mobile.zenopa.com Homepage Homepage
Employment Role Location
Business Sector Advanced
Phone 01494 818 000
View company profile
Please contact the Account Manager for opportunities with this organisation

Novo Nordisk announces FDA approval of Victoza

Posted on 27/01/2010 in Pharmaceutical Company Product News

Novo Nordisk's drug Victoza (liraglutide), which is indicated for the treatment of type 2 diabetes, has been approved for marketing by the Food and Drug Administration (FDA), the firm has announced.

The treatment is the first once-daily human Glucagon-Like Peptide-1 (GLP-1) analogue developed for the treatment of the condition.

It has now been approved by the FDA as an adjunct to diet and exercise to improve glycaemic control in adult patients.

Additionally, it can be used as a monotherapy, as second-line treatment and in combination with common oral medications for diabetes.

Lars Rebien Sorensen, president and chief executive officer of Novo Nordisk, commented: "The ability of Victoza to substantially improve glucose control with a low risk of hypoglycaemia creates an opportunity for more patients with type 2 diabetes to achieve their individual treatment goals."

Earlier this month, Novo Nordisk started its UK-based investigations into the effectiveness of NN9924 - a long-acting oral GLP-1 (Glucagon-Like Peptide-1) analogue for which it has made a payment to Emisphere Technologies.

Other news stories from 27/01/2010

Read more in the Zenopa News Archive

How this news is generated

Becky
Account Manager
for this opportunity

01494 818 026
(Mon to Fri 0830 to 1800 hours)
becky@zenopa.com

Latest News

Novo Nordisk tops endocrinology image poll

Novo Nordisk to initiate trial of diabetes drug Victoza

Novo Nordisk reports solid first quarter performance

Novo Nordisk reports positive diabetes drug trial data

Novo Nordisk commences global haemophilia survey

home | our clients | browse news | browse jobs | links | hotel directory | Valid HTML | copyright © 2010 Zenopa Ltd | terms & conditions of use